Perceptive Xontogeny Venture Fund
New York City, New Yorkperceptivelife.com
Overview
An early-stage venture capital fund, managed as a partnership between Perceptive Advisors and Xontogeny, focused on private investments in life sciences companies. The fund primarily acts as a lead investor in Series A financings, aiming to advance products and technologies from preclinical stages through early clinical development. It is the first in a series of funds, followed by Perceptive Xontogeny Venture Fund II.
Portfolio Companies
14
Website
perceptivelife.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Mercy BioAnalytics | Sep 2025 | Series B | Co-investor |
| Gala Therapeutics | Sep 2025 | Series C | Co-investor |
| Galvanize | Sep 2025 | Series C | Co-investor |
| Zucara Therapeutics Inc. | May 2025 | Series B | Co-investor |
| Marea Therapeutics | Jun 2024 | Series A and B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.